menu

CME: Connecting Science to Psoriatic Arthritis Patient Care

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Connecting Science to Psoriatic Arthritis Patient Care

close
0.50 credits
30 Minutes
Connecting Science to Psoriatic Arthritis Patient Care
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Choosing the appropriate treatment option is essential, but that’s only the first step. How can you then talk about the selected treatment with your psoriatic arthritis patients? Joining Dr. Matt Birnholz to discuss this and more are Drs. Philip Mease and Allan Gibofsky.

  • Learning Objectives

    As a result of participation in this educational activity, participants should increase their ability to:

    1. Describe a current model explaining PsA pathophysiology and mechanisms of action of targeted therapies for PsA.
    2. Apply evidence about effectiveness and safety of targeted therapies for PsA and guiding principles for management of patients with PsA.
    3. Engage patients with PsA in shared decision making regarding goals of treatment, development of treatment plan, and treatment modification
  • Target Audience

    The target audience for this educational activity is rheumatologists and NP/PA rheumatology providers. Other healthcare professionals who treat patients with psoriatic arthritis may benefit from participation in this activity.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

    • Planners (Forefront Collaborative)
    • Krista Jaworski, Forefront Collaborative 
    • Marianna Shershneva, Forefront Collaborative

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    • Faculty: Phillip Mease: AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
    • Faculty: Alan Gibofsky, MD, JD, MACR, FACP, FCLM: AbbVie, Celgene, Pfizer, Lilly, Amgen, Novartis 
  • Accreditation and Credit Designation Statements

    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statements
    Forefront Collaborative designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

    This activity is approved for 0.50 contact hour(s) of continuing education (which includes up to 0.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19093922.  This activity was planned in accordance with AANP Accreditation Standards and Policies.

  • Provider

    This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Associate.

  • Commercial Supporter

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

  • Disclaimer/CME Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Choosing the appropriate treatment option is essential, but that’s only the first step. How can you then talk about the selected treatment with your psoriatic arthritis patients? Joining Dr. Matt Birnholz to discuss this and more are Drs. Philip Mease and Allan Gibofsky.

  • Learning Objectives

    As a result of participation in this educational activity, participants should increase their ability to:

    1. Describe a current model explaining PsA pathophysiology and mechanisms of action of targeted therapies for PsA.
    2. Apply evidence about effectiveness and safety of targeted therapies for PsA and guiding principles for management of patients with PsA.
    3. Engage patients with PsA in shared decision making regarding goals of treatment, development of treatment plan, and treatment modification
  • Target Audience

    The target audience for this educational activity is rheumatologists and NP/PA rheumatology providers. Other healthcare professionals who treat patients with psoriatic arthritis may benefit from participation in this activity.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

    • Planners (Forefront Collaborative)
    • Krista Jaworski, Forefront Collaborative 
    • Marianna Shershneva, Forefront Collaborative

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    • Faculty: Phillip Mease: AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
    • Faculty: Alan Gibofsky, MD, JD, MACR, FACP, FCLM: AbbVie, Celgene, Pfizer, Lilly, Amgen, Novartis 
  • Accreditation and Credit Designation Statements

    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statements
    Forefront Collaborative designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

    This activity is approved for 0.50 contact hour(s) of continuing education (which includes up to 0.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19093922.  This activity was planned in accordance with AANP Accreditation Standards and Policies.

  • Provider

    This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Associate.

  • Commercial Supporter

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

  • Disclaimer/CME Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/28/20